Immuno Oncology Assays Market Size, Share, Growth, Emerging Trends, Top 10 Players And Industry Outlook
Summary
- In July 2020, HTG Molecular Diagnostics, Inc. (US) launched its HTG EdgeSeq Pan B-Cell Lymphoma Panel.
- In August 2019, Agilent Technologies, Inc. (US), along with The National University of Singapore (NUS) and the National University Hospital (NUH), established Singapore's first integrated translational R&D hub.
This study involved four major activities in estimating the current size of the immuno-oncology assays market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
Expected Revenue Growth:
[214 Pages Report] The global immuno-oncology assays market is projected to reach USD 7.9 billion by 2026 from USD 4.4 billion in 2021, at a CAGR of 12.5%.
Download PDF Brochure:
Key Factors Driving Market Growth:
Market growth is driven by the increased demand for personalized medicine, rising incidence of cancer and the growing adoption of targeted therapy, and the growing significance of companion diagnostics in drug development.
Immuno-Oncology Assays Market (MarketsandMarkets)
Competitive Landscape:
The competitive landscape includes the analysis of the key growth strategies adopted by major players to expand their global presence and increase their shares in the market. The key growth strategies adopted by the top players in the market include product launches and approvals, agreements, expansions, and acquisitions. Product approvals and launches were the most widely adopted growth strategies by market players in the last three years to garner a larger share of the market.
Key Players:
- Thermo Fisher Scientific, Inc. (US),
- F. Hoffmann-La Roche Ltd. (Switzerland),
- Agilent Technologies, Inc. (US),
- Illumina, Inc. (US),
- NanoString Technologies, Inc. (US),
- Sartorius AG (Germany),
- HTG Molecular Diagnostics, Inc. (US),
- QIAGEN N.V. (Netherlands),
- Merck Millipore (US),
- PerkinElmer, Inc. (US)
Get crucial industry insights: https://www.prnewswire.com/news-releases/immuno-oncology-assays-market-worth-7-9-billion-by-2026--exclusive-report-by-marketsandmarkets-301274680.html
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.